

ANNUAL  
**PHARMA**  
SUMMIT 2024



**Positioning India as  
The Pharmaceutical  
Innovation Hub**

**Thursday, 26 September 2024**

**New Delhi**

# Overview

India's **pharmaceutical sector**, currently valued at **USD 50 billion**, is one of the fastest-growing industries in the country. It is expected to reach **USD 65 billion** by 2024 and anticipated to double its value to **USD 130 billion** by 2030. The sector plays a prominent role in the global pharmaceutical industry. The Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally and ranks third in pharmaceutical production by volume. Some of the major segments of the Indian Pharma Industry include generic drugs, OTC medicines, bulk drugs, vaccines, biosimilars and biologics.

While India has made rapid progress in manufacturing and exporting generic drugs, it still imports the majority of the APIs and KSMs for drug manufacturing. One of the major reasons attributing to higher imports is the lack of sufficient investments towards Research and Development (R&D) by the Pharma sector, apart from other sectors in India. India's overall expenditure on R&D stood at 0.8% of its GDP in 2021, which is among the lowest in the world. The pharma companies in India invested a meagre 7.2% of their sales value in R&D in 2021, amounting to USD 3 billion. Comparatively, the US spent USD 50-60 billion, and China invested USD 15-20 billion in pharma R&D during the same period.

To enhance the focus on R&D in the Pharma sector, the Government has taken several measures including announcement of the National Policy on Research & Development and Innovation in the Pharma-Med Tech Sector and Research Linked Incentive Scheme for Promotion of Research and Innovation in Pharma MedTech Sector (PRIP Scheme).

With this context, ASSOCHAM is organizing its 'Annual Pharma Summit 2024' themed "Positioning India as the Pharmaceutical Innovation Hub" to assimilate key expectations of the Indian Pharma industry with a focus on Research and Development.

## Key highlights



First of its kind integrated conclave for innovation in pharma



Participation from Central and State Governments



200+ Pharma professionals from across the country



Cross-Linkages and Networking with potential clients and partners



20+ Pharma experts/speakers



B2B meetings and Networking opportunities



Pharma Excellence Awards 2023-24



# ASOCHAM PHARMA EXCELLENCE AWARDS 2023-24



Indian Pharmaceutical Industry (IPI) has achieved high growth rate largely in terms of volume during the last two decades and has a strong footprint globally in generic segment and is the third largest in terms of volume and thirteenth largest in terms of value.

Assocham Pharma Excellence Awards 2023-24, invites nominations from pharma companies in India who have demonstrated unwavering commitment to innovation and are redefining the pharmaceutical landscape through their outstanding contribution to the sector.

## Award categories



## Award nomination fees

Processing fees (per category) + applicable GST

(Large / PSU / Medium)		Micro & Small Industry & Startups	
ASOCHAM Members	Non-Members	ASOCHAM Members	Non-Members
INR 18,000/-	INR 20,000/-	INR 12,000/-	INR 15,000/-

## Why should you nominate?



Stand out from the competition to attract new business



Showcase your top projects, designs, innovations among industry



Improve brand awareness and promote your business to new customers



Celebrate your success & achievement with industry players



Boost staff morale and motivation among employees



Get recognition for your hard work, achievements, & innovations

# Key area of discussions

## PRIP (Promotion of Research and Innovation in Pharma MedTech Sector): India opportunities for investments

- Need for investments in pharma R&D – strategic, captive and VC investments
- Role of emerging technologies and futuristic diseases in revolutionizing the sector
- Key benefits that India offers to attract global companies to invest in R&D
- Collaboration opportunities and integration with academia, institutions, and industry
- Leveraging benefits of recent FTAs with different countries and India's uplifted ranking in WIPO
- Emerging and dedicated infrastructure like drug parks, MedTech parks, and focused state policies
- Cross-country research partnerships, like India-Israel, India-UK, India-EU, India-US, India-Japan

## Driving Business growth: Building a conducive ecosystem for Innovation and Product Development

- Initiatives, schemes, and programs undertaken by the Government to promote R&D
- Status of on-ground implementation of the schemes/ programs
- Impediments restricting the industry to invest in R&D in India across stages i.e., early drug discovery, pre-clinical, clinical trials and regulatory approvals
- Industry trends and best practices for efficient bio-medical waste management
- Recommendations to promote investments in R&D across aspects like skilling, IP awareness and in-house IP creation, increased funding, enabling policy ecosystem, etc

## Who should attend



Govt Officials



Scientists & Technicians



Compliance



Policy Makers



Laboratory In charge



Research & Development



Quality Control and Assurance (QA/QC)



Information Technology



Others (Medical and Technology Student)

For more information, please contact



**The Associated Chambers of Commerce and Industry of India**

4th Floor, YMCA Cultural Centre and Library Building,

01 Jai Singh Road, New Delhi -110001 **Tel:** +91-11-46550555 **Fax:** +91-11-23017008/9

**Ms. Sumita Chakravarty**

M: +91 9967537733

E: sumita.chakravarty@assocharm.com

**Ms. Jasmeet Nagpal**

M: +91 9818479744

E: jasmeet.nagpal@assocharm.com

**Mr. Vishvvarat Kanojia**

M: +91 9871057791

E: vishvvarat@assocharm.com